« Back
Home /
Trametinib (DMSO solvate)

Trametinib (DMSO solvate)

Manufacturer	MedChem Express
Category	Oncology Neuroscience Neural Signaling Inhibitors & Compound Libraries Small Molecules By Organ Lung Cancer Colorectal Cancer
Type	Inhibitors
Specific against	other
Clone	N/A
Amount	100 mg
Item no.	HY-10999A-100mg
Targets	MEK; Apoptosis
CASRN	1187431-43-1
eClass 6.1	30220300
eClass 9.0	32160605
Available
Product Description	Trametinib (DMSO solvate) (GSK-1120212 (DMSO solvate); JTP-74057 (DMSO solvate)) is an orally active MEK inhibitor that inhibits MEK1 and MEK2 with IC50s of about 2 nM. Trametinib (DMSO solvate) activates autophagy and induces apoptosis[1][2].
StorageTemperature	-20°C, 3 years; 4°C, 2 years (Powder)
Shipping	Room Temperature
Manufacturers Applications	Cancer-Kinase/protease
MolecularWeight	693.53
Clinical_Information	Launched
Manufacturers Research_Area	Cancer
Solubility	DMSO : 3.33 mg/mL (ultrasonic)
Manufacturers Target	Apoptosis; MEK
Isoform	MEK1; MEK2
Pathway	Apoptosis; MAPK/ERK Pathway
Manufacturers Product type	Reference compound

Note: The presented information and documents (Manual, Product Datasheet, Safety Datasheet and Certificate of Analysis) correspond to our latest update and should serve for orientational purpose only. We do not guarantee the topicality. We would kindly ask you to make a request for specific requirements, if necessary.

All products are intended for research use only (RUO). Not for human, veterinary or therapeutic use.

Request Data Sheet

Request product datasheet

HY-10999A-100mg-safety-datasheet.pdf